TipRanks
Careium AB (SE:CARE)
:CARE
Sweden Market
Want to see SE:CARE full AI Analyst Report?

Careium AB (CARE) AI Stock Analysis

1 Followers

Top Page

SE:CARE

Careium AB

(CARE)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - Gpt-5.6Sol)
Rating:69Neutral
Price Target:
kr32.00
▲(11.11% Upside)
Action:Reiterated
Date:10/24/26
The score is driven primarily by improving financial performance (profitability rebound and healthier leverage), supported by a positive technical trend with moderate momentum. Valuation is the main limiter, as a ~19 P/E with no dividend yield looks only fair relative to modest margins and uneven cash-flow consistency.
Positive Factors
Revenue Recovery
The return to revenue growth indicates renewed demand and improving commercial execution after the prior dip. Sustained expansion would increase the installed base supporting service revenue, improve operating leverage, and strengthen Careium’s ability to reinvest in its telecare platform.
Negative Factors
Modest Profitability
Although profitability has rebounded, a roughly 4% net margin leaves limited room for cost increases or execution setbacks. The decline from stronger 2024 margins suggests operating leverage remains constrained, which may limit earnings growth even if revenue continues expanding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The return to revenue growth indicates renewed demand and improving commercial execution after the prior dip. Sustained expansion would increase the installed base supporting service revenue, improve operating leverage, and strengthen Careium’s ability to reinvest in its telecare platform.
Read all positive factors

Careium AB (CARE) vs. iShares MSCI Sweden ETF (EWD)

Careium AB Business Overview & Revenue Model

Company Description
Careium AB (Publ), established in 1974 and headquartered in Malmö, Sweden, specializes in providing technologically advanced care solutions across numerous European nations, including Sweden, Norway, the United Kingdom, and the Netherlands. Their ...
How the Company Makes Money
Careium makes money by selling and supporting telecare offerings that combine hardware and ongoing service delivery. Revenue is typically generated through: (1) service fees for operating telecare solutions, which can include hosting/operating the...

Careium AB Financial Statement Overview

Summary
Financials show a clear rebound with positive operating profit and net income plus renewed TTM revenue growth (~5%). Balance sheet leverage is manageable and improving (debt-to-equity ~0.29), but profitability remains modest (net margin ~4%) and cash flow consistency is a key risk given uneven cash conversion and prior volatility.
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
64
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue961.70M854.10M870.70M824.60M725.10M587.50M
Gross Profit419.40M375.10M373.70M340.50M273.70M240.30M
EBITDA142.30M120.60M150.60M137.90M67.90M65.10M
Net Income50.60M35.80M58.40M37.90M-8.60M4.70M
Balance Sheet
Total Assets1.14B1.09B1.05B961.40M992.10M1.05B
Cash, Cash Equivalents and Short-Term Investments28.00M54.90M31.90M31.50M39.90M142.50M
Total Debt219.20M209.70M196.80M225.30M322.70M292.30M
Total Liabilities424.70M407.40M371.40M361.90M425.50M500.20M
Stockholders Equity717.70M681.50M678.20M599.50M566.60M551.50M
Cash Flow
Free Cash Flow63.50M51.30M36.90M61.90M-87.10M-70.90M
Operating Cash Flow131.90M143.40M92.90M111.90M-21.10M-19.80M
Investing Cash Flow-97.10M-102.20M-56.00M-50.00M-68.70M-163.70M
Financing Cash Flow-37.50M-13.70M-39.60M-69.70M-15.10M291.00M

Careium AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price28.80
Price Trends
50DMA
27.82
Positive
100DMA
27.99
Positive
200DMA
25.19
Positive
Market Momentum
MACD
0.44
Negative
RSI
60.04
Neutral
STOCH
42.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Positive. The current price of 28.8 is above the 20-day moving average (MA) of 27.75, above the 50-day MA of 27.82, and above the 200-day MA of 25.19, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 60.04 is Neutral, neither overbought nor oversold. The STOCH value of 42.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CARE.

Careium AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
kr614.52M12.20―2.85%9.56%20.95%
69
Neutral
kr710.33M14.31――12.86%18.01%
61
Neutral
kr204.89M-2.37――-10.30%-11.59%
58
Neutral
kr115.23M14.65―1.34%3.50%58.41%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
40
Underperform
kr40.19M-2.31-58.52%1.06%-16.09%78.68%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:CARE
Careium AB
29.20
2.90
11.03%
SE:MVIR
Medivir AB
1.61
1.09
206.67%
SE:BOUL
Boule Diagnostics AB
1.04
-5.06
-83.03%
SE:NNH
New Nordic Healthbrands AB
18.60
-6.10
-24.69%
SE:DEDI
Dedicare AB
61.50
17.99
41.33%
SE:PTRK
Physitrack Limited
12.60
-2.70
-17.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2026